In our study, as discussed in Figure 5, pathway enrichment analysis indicated that targeting the PI3K/Akt/mTOR signaling pathway provides a potential therapeutic insight for HCC treatment. This evidence concerns the gene AKT1 and hepatocellular carcinoma.